Shots:
- AbbVie has reported the P-III (CERVINO) trial assessing etentamig (Q4W) vs standard available therapies in pts with R/R MM who have received ≥2 prior lines of therapy, incl. exposure to a proteasome inhibitor, an immunomodulatory drug & an anti-CD38 mAb
- At the mFU of 11.4mos. (n=393 pts; median 3 prior lines), trial met its dual 1EPs of ORR (74% vs 45.7%) & improved PFS by 60%, with PFS benefit observed across all subgroups evaluated. 12mos. OS rate was 87.9% vs 72%; OS efficacy boundary was not crossed at the data cutoff. Data to be presented at International Myeloma Society’26
- At the first planned efficacy interim analysis, the CERVINO trial showed significant benefit, prompting the IDMC to recommend unblinding; AbbVie will discuss the results with global regulators to determine next steps for etentamig
Ref: PRnewswire | Image: AbbVie | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
